Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,762 | -3,102 | -3,555 | -5,540 | -6,678 |
| Depreciation Amortization | 7 | 9 | 11 | 13 | 242 |
| Accounts payable and accrued liabilities | -569 | -418 | 807 | 331 | -170 |
| Other Working Capital | 143 | 473 | 446 | 4,472 | 2,142 |
| Other Operating Activity | 1,897 | 466 | -751 | -289 | 379 |
| Operating Cash Flow | $-3,284 | $-2,572 | $-3,042 | $-1,013 | $-4,086 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 63 |
| Debt Issued | 2,853 | 2,475 | 1,628 | 3,160 | 3,225 |
| Debt Repayment | -100 | N/A | N/A | N/A | N/A |
| Common Stock Issued | -5 | -283 | N/A | 962 | 419 |
| Other Financing Activity | 0 | 0 | -260 | -98 | -106 |
| Financing Cash Flow | $2,748 | $2,192 | $1,368 | $4,024 | $3,600 |
| Exchange Rate Effect | -1 | -25 | -2 | -1 | -8 |
| Beginning Cash Position | 1,027 | 1,432 | 3,107 | 97 | 591 |
| End Cash Position | 490 | 1,027 | 1,432 | 3,107 | 97 |
| Net Cash Flow | $-537 | $-405 | $-1,675 | $3,010 | $-494 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,284 | -2,572 | -3,042 | -1,013 | -4,086 |
| Free Cash Flow | -3,284 | -2,572 | -3,042 | -1,013 | -4,086 |